| Literature DB >> 21730022 |
Yujia Cao1, Lu Zhang, Pacharee Ritprajak, Fumihiko Tsushima, Pornpan Youngnak-Piboonratanakit, Yosuke Kamimura, Masaaki Hashiguchi, Miyuki Azuma.
Abstract
B7-H1 (CD274), a member of the B7 family of coinhibitory molecules, is often induced in human tumors and its expression is closely correlated with a poor prognosis or higher malignancy grade. Tumor-associated B7-H1 is implicated in mechanisms of immune escape. Under inflammatory conditions, B7-H1 is also inducible in normal epithelial cells, but little is known about its involvement in the conversion of normal cells to tumor cells. We recently found that skin-specific expression of B7-H1 accelerates chemically induced carcinogenesis of squamous cell carcinoma (SCC), despite impaired skin inflammatory responses, in B7-H1 transgenic (B7-H1tg) mice. B7-H1tg-derived keratinocytes (KC) and SCCs exhibited a marked reduction of E-cadherin, and B7-H1tg-originated SCCs showed elevated expression of the transcription factors Slug and Twist, suggesting that B7-H1 overexpression in KCs promotes the epithelial-mesenchymal transition and accelerates carcinogenesis. This review discusses the diverse functions of B7-H1 in carcinogenesis and cancer progression, and considers future directions for developing cancer therapy targeting B7-H1. ©2011 AACR.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21730022 DOI: 10.1158/0008-5472.CAN-11-0527
Source DB: PubMed Journal: Cancer Res ISSN: 0008-5472 Impact factor: 12.701